|
1
|
Saji S: Evolving approaches to metastatic
breast cancer patients pre-treated with anthracycline and taxane.
BioDrugs. 27:469–478. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Riou G, Mathieu MC, Barrois M, Le Bihan
ML, Ahomadegbe JC, Bénard J and Lê MG: c-erbB-2 (HER-2/neu) gene
amplification is a better indicator of poor prognosis than protein
over-expression in operable breast-cancer patients. Int J Cancer.
95:266–270. 2001.PubMed/NCBI
|
|
3
|
Pegram MD, Finn RS, Arzoo K, Beryt M,
Pietras RJ and Slamon DJ: The effect of HER-2/neu overexpression on
chemotherapeutic drug sensitivity in human breast and ovarian
cancer cells. Oncogene. 15:537–547. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang GS, Zhu H and Bi SJ: Pathological
features and prognosis of different molecular subtypes of breast
cancer. Mol Med Report. 6:779–782. 2012. View Article : Google Scholar
|
|
5
|
Heyerdahl H, Abbas N, Brevik EM, Mollatt C
and Dahle J: Fractionated therapy of HER2-expressing breast and
ovarian cancer xenografts in mice with targeted alpha emitting
227Th-DOTA-p-benzyl-trastuzumab. PLoS One. 7:e423452012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vu T and Claret FX: Trastuzumab: Updated
mechanisms of action and resistance in breast cancer. Front Oncol.
2:622012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maeda S, Saimura M, Minami S, Kurashita K,
Nishimura R, Kai Y, Yano H, Mashino K, Mitsuyama S, Shimokawa M, et
al: Efficacy and safety of eribulin as first-to third-line
treatment in patients with advanced or metastatic breast cancer
previously treated with anthracyclines and taxanes. Brest.
32:66–72. 2017. View Article : Google Scholar
|
|
8
|
Berger C, Madshus IH and Stang E:
Cetuximab in combination with anti-human IgG antibodies efficiently
down-regulates the EGF receptor by macropinocytosis. Exp Cell Res.
318:2578–2591. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Meng S, Tripathy D, Shete S, Ashfaq R,
Saboorian H, Haley B, Frenkel E, Euhus D, Leitch M, Osborne C, et
al: uPAR and HER-2 gene status in individual breast cancer cells
from blood and tissues. Proc Natl Acad Sci USA. 103:17361–17365.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Su CY, Liu YP, Yang CJ, Lin YF, Chiou J,
Chi LH, Lee JJ, Wu AT, Lu PJ, Huang MS and Hsiao M: Plasminogen
activator inhibitor-2 plays a leading prognostic role among
protease families in non-small cell lung cancer. PLoS One.
10:e01334112015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Märkl B, Renk I, Oruzio DV, Jähnig H,
Schenkirsch G, Schöler C, Ehret W, Arnholdt HM, Anthuber M and
Spatz H: Tumour budding, uPA and PAI-1 are associated with
aggressive behaviour in colon cancer. J Surg Oncol. 102:235–241.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim TD, Song KS, Li G, Choi H, Park HD,
Lim K, Hwang BD and Yoon WH: Activity and expression of
urokinase-type plasminogen activator and matrix metalloproteinases
in human colorectal cancer. BMC Cancer. 6:2112006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Foekens JA, Peters HA, Look MP, Portengen
H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder
ME, Henzen-Logmans SC, et al: The urokinase system of plasminogen
activation and prognosis in 2780 breast cancer patients. Cancer
Res. 60:636–643. 2000.PubMed/NCBI
|
|
14
|
Look MP, van Putten WL, Duffy MJ, Harbeck
N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M,
Eppenberger-Castori S, et al: Pool analysis of prognostic impact of
urokinase-type plasminogen activator and its inhibitor PAI-1 in
8377 breast cancer patients. J Natl Cancer Inst. 94:116–128. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Laufs S, Schumacher J and Allgayer H:
Urokinase-receptor (u-PAR): An essential player in multiple games
of cancer: A review on its role in tumors progression, invasion,
metastasis, proliferation/dormancy, clinical outcome and minimal
residual disease. Cell Cycle. 5:1760–1771. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sidenius N and Blasi F: The urokinase
plasminogen activator system in cancer: Recent advances and
implication for prognosis and therapy. Cancer Metastasis Rev.
22:205–222. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu XW, Duan HF, Gao LH, Pan SY, Li YM, Xi
Y, Zhao SR, Yin L, Li JF, Chen HP and Wu CT: Inhibition of tumors
growth and metastasis by ATF-Fc, an engineered antibody targeting
urokinase receptor. Cancer Biol Ther. 7:651–659. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu X, Xiao C, Huang Z, Guo Z, Zhang Z and
Li Z: Pilot production of u-PA with porous microcarrier cell
culture. Cytotechnology. 33:13–19. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tanaka M, Obata T and Sasaki T: Evaluation
of antitumor effects of docetaxel (Taxotere) on human gastric
cancer in vitro and in vivo. Eur J Cancer. 32A:226–230. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Evans BD, Smith IE, Shorthouse AJ and
Millar JL: A comparison of the response of human lung carcinoma
xenografts to vindesine and vincristine. Br J Cancer. 45:466–468.
1982. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wolff AC, Hammond ME, Schwartz JN, Hagerty
KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer
A, et al: American Society of Clinical Oncology/College of American
Pathologists guideline recommendations for human epidermal growth
factor receptor 2 test in breast cancer. J Clin Oncol. 25:118–145.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Glasgow MD and Chougule MB: Recent
developments in active tumor targeted multifunctional nanoparticles
for combination chemotherapy in cancer treatment and imaging. J
Biomed Nanotechnol. 11:1859–1898. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Griffiths R, Mikhael J, Gleeson M, Danese
M and Dreyling M: Addition of rituximab to chemotherapy alone as
first-line therapy improves overall survival in elderly patients
with mantle cell lymphoma. Blood. 118:4808–4816. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Seal MD, Speers CH, O'Reilly S, Gelmon KA,
Ellard SL and Chia SK: Outcomes of woman with early-stage breast
cancer receiving adjuvant trastuzumab. Curr Oncol. 19:197–201.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Altomare I, Bendell JC, Bullock KE, Uronis
HE, Morse MA, Hsu SD, Zafar SY, Blobe GC, Pang H, Honeycutt W, et
al: A phase II trial of bevacizumab plus everolimus for patients
with refractory metastatic colorectal cancer. Oncologist.
16:1131–1137. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fleitas T, Martínez-Sales V, Vila V,
Reganon E, Mesado D, Martín M, Gómez-Codina J, Montalar J and
Reynés G: Circulating endothelial cells and microparticles as
prognostic markers in advanced non-small cell lung cancer. PLoS
One. 7:e473652012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vacchelli E, Pol J, Bloy N, Eggermont A,
Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, et
al: Trial watch: Tumor-targeting monoclonal antibodies for
oncological indications. Oncoimmunology. 4:e9859402015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kargiotis O, Chetty C, Gogineni V, Gondi
CS, Pulukuri SM, Kyritsis AP, Gujrati M, Klopfenstein JD, Dinh DH
and Rao JS: uPA/uPAR downregulation inhibits radiation-induced
migration, invasion and angiogenesis in IOMM-Lee menigioma cells
and decreases tumors growth in vivo. Int J Oncol. 33:937–947.
2008.PubMed/NCBI
|
|
29
|
Rabbani SA and Gladu J: Urokinase receptor
antibody can reduce tumors volume and detect the presence of occult
tumors metastases in vivo. Cancer Res. 62:2390–2397.
2002.PubMed/NCBI
|
|
30
|
Kobayashi H, Gotoh J, Shinohara H, Moniwa
N and Terao T: Inhibition of the metastasis of Lewis lung carcinoma
by antibody against urokinase-type plasminogen activator in the
experimental and spontaneous metastasis model. Thromb Haemost.
71:474–480. 1994.PubMed/NCBI
|
|
31
|
Beloglazova IB, Beabealashvilli RSh,
Gursky YG, Bocharov EV, Mineev KS, Parfenova EV and Tkachuk VA:
Structural investigations of recombinant urokinase growth
factor-like domain. Biochemistry (Mosc). 78:517–530. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bifulco K, Longanesi-Cattani I, Franco P,
Pavone V, Mugione P, Di Carluccio G, Masucci MT, Arra C, Pirozzi G,
Stoppelli MP and Carriero MV: Single amino acid substitutions in
the chemotactic sequence of urokinase receptor modulate cell
migration and invasion. PLoS One. 7:e448062012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Crowley CW, Cohen RL, Lucas BK, Liu G,
Shuman MA and Levinson AD: Prevention of metastasis by inhibition
of the urokinase receptor. Proc Natl Acad Sci USA. 90:5021–5025.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chandran Indira V, Eppenberger-Castori S,
Venkatesh T, Vine KL and Ranson M: HER2 and uPAR cooperativity
contribute to metastatic phenotype of HER2-positive breast cance.
Oncoscience. 2:207–224. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Oliveras-Ferraros C, Corominas-Faja B,
Cufí S, Vazquez-Martin A, Martin-Castillo B, Iglesias JM,
López-Bonet E, Martin AG and Menendez JA: Epithelial-to-mesenchymal
transition (EMT) confers primary resistance to trastuzumab
(Herceptin). Cell Cycle. 11:4020–4032. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Capelan M, Pugliano L, De Azambuja E,
Bozovic I, Saini KS, Sotiriou C, Loi S and Piccart-Gebhart MJ:
Pertuzumab: New hope for patients with HER2-positive breast cancer.
Ann Oncol. 24:273–282. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gajria D and Chandarlapaty S:
HER2-amplified breast cancer: Mechanisms of trastuzumab resistance
and novel targeted therapies. Expert Rev Anticancer Ther.
11:263–275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Baylin SB and Jones PA: A decade of
exploring the cancer epigenome-biological and translational
implications. Nat Rev Cancer. 11:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Esteller M: Cancer epigenomics: DNA
methylomes and histone-modification maps. Nat Rev Genet. 8:286–298.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Meng S, Tripathy D, Shete S, Ashfaq R,
Saboorian H, Haley B, Frenkel E, Euhus D, Leitch M, Osborne C, et
al: uPA and HER-2 gene status in individual breast cancer cells
from blood and tissues. Proc Natl Acad Sci USA. 103:17361–17365.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pierga JY, Bonneton C, Magdelénat H,
Vincent-Salomon A, Nos C, Boudou E, Pouillart P, Thiery JP and de
Cremoux P: Real-time quantitative PCR determination of
urokinase-type plasminogen activator receptor (uPAR) expression of
isolated micrometastatic cells from bone marrow of breast cancer
patients. Int J Cancer. 114:291–298. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu D, Ghiso Aguirre J, Estrada Y and
Ossowski L: EGFR is a transducer of the urokinase receptor
initiated signal that is required for in vivo growth of a human
carcinoma. Cancer Cell. 1:445–457. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jo M, Thomas KS, O'Donnell DM and Gonias
SL: Epidermal growth factor receptor-dependent and -independent
cell-signaling pathways originating from the urokinase receptor. J
Biol Chem. 278:1642–1646. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Guerrero J, Santibañez JF, González A and
Martínez J: EGF receptor transactivation by urokinase receptor
stimulus through a mechanism involving Src and matrix
metalloproteinases. Exp Cell Res. 292:201–208. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li C, Cao S, Liu Z, Ye X, Chen L and Meng
S: RNAi-mediated downregulation of uPAR synergizes with targeting
of HER2 through the ERK pathways in breast cancer cells. Int J
Cancer. 127:1507–1516. 2010. View Article : Google Scholar : PubMed/NCBI
|
